Drug Target Identified for Chemotherapy-Resistant Ovarian, Breast Cancer

February 4, 2019 5:00 pm

By Tamara Bhandari

Study finds mimic for BRCA genes that could be targeted to improve treatment

People who inherit a faulty copy of the so-called “breast cancer genes” BRCA1 and BRCA2 are at high risk of cancer. About 10 percent … Read more

FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers

December 19, 2018 5:00 pm

By Brielle Benyon

The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a

Read more

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

October 25, 2018 1:11 am

By 

Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more

Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years

October 22, 2018 4:35 pm

By 

A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.

Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more

BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

September 28, 2018 8:37 pm

The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.

PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more

New Developments in Ovarian Cancer Treatment Are Showing Promise

September 14, 2018 4:29 pm

Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.

But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more

The Future of Ovarian Cancer: PARP Inhibition ‘Leading the Way’

July 6, 2018 8:58 pm
By Brielle Urciuoli
PARP inhibitors have made for new and exciting treatment options for ovarian cancer, but there is still much more work to be done, according to Dennis J. Slamon, M.D., Ph.D.

Slamon, who is the director of both

Read more

Olaparib Plus Vistusertib Promising in Early Trial

June 8, 2018 9:48 pm

The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504Read more

Webinar: PARP Inhibitors: What You Need to Know

October 18, 2017 7:32 pm

Join OCRFA on Monday, Oct. 23rd at 6:00pm ET for a webinar on PARP Inhibitors with Dr. Ursula Matulonis of Dana-Farber Cancer Institute.

There is a great amount of excitement in the ovarian cancer clinical and research communities about the … Read more

Another Win for PARP Inhibition in Ovarian Cancer

September 12, 2017 4:09 pm

Women with recurrent, platinum-sensitive ovarian cancer lived twice as long without disease progression when they received maintenance therapy with the PARP inhibitor rucaparib (Rubraca), a randomized trial showed.

Overall, patients treated with rucaparib had a median progression-free survival of 10.8 … Read more

PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment

July 11, 2017 5:53 pm

With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more

Pairing PARP Inhibitors With Other Drug Types the Next Frontier for BRCA-Mutated Ovarian Cancers

June 13, 2017 6:35 pm

The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and combining the PARP inhibitors that accomplish that with other types of therapies will be the focus of treatment … Read more

Ovarian Cancer Patients Actively Seeking PARP Inhibitor Therapy, Expert Says

May 15, 2017 5:19 pm

In the treatment of advanced ovarian cancer, PARP inhibitors, including olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula), are stealing the limelight, explains Dennis Scribner, MD.

In an interview with Targeted Oncology, Scribner, a gynecologic oncologist at Arizona Oncology, discussed … Read more

Ending a Dry Spell of Years Without Treatment for Ovarian Cancer

May 3, 2017 7:04 pm

Teri Woodhull is decidedly proactive. A strong family history of breast cancer led her to undergo a preventive bilateral mastectomy at age 30. Seventeen years later, she was diagnosed with stage 3b high-grade serous epithelial ovarian cancer.

“I do have … Read more

PARP Inhibitor Approvals Offer Ovarian Cancer Patients New Hope

April 18, 2017 5:20 pm

The ovarian cancer treatment paradigm underwent another transformation near the end of 2016 with the FDA approval of the PARP inhibitor rucaparib (Rubraca) for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of … Read more

PARP Inhibitor Active in BRCA Subgroups

March 14, 2017 5:52 pm

Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.

Results showed a median PFS of … Read more

Tesaro Opens Expanded Program of PARP inhibitor for U.S. Ovarian Cancer Patients

January 18, 2017 7:31 pm

Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more

PARP Inhibitor Shows Benefit in Ovarian Cancer

November 28, 2016 8:01 pm

Lynparza (olaparib) demonstrated improved progression-free survival (PFS) compared to the placebo arm for patients with ovarian cancer, according to findings from the phase 3 SOLO-2 trial. The single-agent PARP inhibitor was tested in the maintenance setting for patients with advanced … Read more